Erika Ruiz-Garcia, trained in oncology in Mexico City and later specialized in gastrointestinal oncology. She completed a fellowship in Translational Research at the Institute Gustave Roussy (France) and was a clinical observer in the Gastrointestinal Service Unit in the Department of Medicine at Memorial Sloan-Kettering Cancer Center (USA). Currently, is a Professor of the Department of Gastrointestinal Medical Oncology and Chief of the Translational Medicine Laboratory at Instituto Nacional de Cancerologia in Mexico City. Over the past 10 years, she has been involved in natural and international clinical and translational research projects, some of them under her leadership in GI cancer. Dr. Erika Ruiz-Garcia has published 82 peer-reviewed articles (on pubmed; H-factor:24; 1727 citations) in prestigious journals including, Journal of Clinical Oncology, European Journal of Cancer, British Journal of Cancer, and Frontiers Oncology. She has been a co-editor of the textbook Translational Research and Onco-Omics Applications in the Era of Cancer Personal Genomics (Springer Nature 2019) and has been invited as Topic Editor of Frontiers Oncology section Molecular and Cellular Oncology. She won Science and Technology Award (2016) from CONACyT Mexico with “Methylation Landscape and Human Breast Cancer Cells in Response to Dietary Compound Resveratrol” and in 2019, she won the Mexican National Oncology Award with “Antiproliferative effect of the endogenous cannabinoids agonist in gastric cancer cells lines”. Erika Ruiz-García is a member of several scientific organizations like ESMO, ASCO, AACR and she has been part of the ESMO Faculty Group of Gastrointestinal Tumors, as well, Member of Gastrointestinal Cancer Guideline Advisory Group (ASCO).